Thus, in patients with advanced and recurrent disease, irosustat showed much lower clinical benefit compared to progestin megestrol acetate, which questioned the suitability of STS inhibitors for treatment of endometrial cancer. The gene discussed is STS; the disease is endometrial cancer.